FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379206982> ?p ?o ?g. }

• W4379206982 abstract "Abstract Background Compound with cancer stem cell (CSC)-suppressing activity is promising for the improvement of lung cancer clinical outcomes. Toward this goal, we discovered the CSC-targeting activity of resveratrol (RES) analog moscatilin (MOS). With slight structural modification from RES, MOS shows dominant cytotoxicity and CSC-suppressive effect. Methods Three human lung cancer cell lines, namely H23, H292, and A549, were used to compare the effects of RES and MOS. Cell viability and apoptosis were determined by the MTT assay and Hoechst33342/PI double staining. Anti-proliferative activity was determined by colony formation assay and cell cycle analysis. Intracellular reactive oxygen species (ROS) were measured by fluorescence microscopy using DCFH 2 -DA staining. CSC-rich populations of A549 cells were generated, and CSC markers, and Akt signaling were determined by Western blot analysis and immunofluorescence. Molecular docking and molecular dynamics (MD) simulations were used to predict the possible binding of the compound to Akt protein. Results In this study, we evaluated the effects of RES and MOS on lung cancer and its anti-CSC potential. Compared with RES, its analog MOS more effectively inhibited cell viability, colony formation, and induced apoptosis in all lung cancer cell lines (H23, H292, and A549). We further investigated the anti-CSC effects on A549 CSC-rich populations and cancer adherent cells (A549 and H23). MOS possesses the ability to suppress CSC-like phenotype of lung cancer cells more potent than RES. Both MOS and RES repressed lung CSCs by inhibiting the viability, proliferation, and lung CSC-related marker CD133. However, only MOS inhibits the CSC marker CD133 in both CSC-rich population and adherent cells. Mechanistically, MOS exerted its anti-CSC effects by inhibiting Akt and consequently restored the activation of glycogen synthase kinase 3β (GSK-3β) and decreased the pluripotent transcription factors (Sox2 and c-Myc). Thus, MOS inhibits CSC-like properties through the repression of the Akt/GSK-3β/c-Myc pathway. Moreover, the superior inhibitory effects of MOS compared to RES were associated with the improved activation of various mechanism, such as cell cycle arrest at G2/M phase, production of ROS-mediated apoptosis, and inhibition of Akt activation. Notably, the computational analysis confirmed the strong interaction between MOS and Akt protein. MD simulations revealed that the binding between MOS and Akt1 was more stable than RES, with MM/GBSA binding free energy of − 32.8245 kcal/mol at its allosteric site. In addition, MOS interacts with Trp80 and Tyr272, which was a key residue in allosteric inhibitor binding and can potentially alter Akt activity. Conclusions Knowledge about the effect of MOS as a CSC-targeting compound and its interaction with Akt is important for the development of drugs for the treatment of CSC-driven cancer including lung cancer." @default.
• W4379206982 created "2023-06-04" @default.
• W4379206982 creator A5013984804 @default.
• W4379206982 creator A5019794851 @default.
• W4379206982 creator A5060090809 @default.
• W4379206982 creator A5061536229 @default.
• W4379206982 creator A5064398646 @default.
• W4379206982 creator A5065121008 @default.
• W4379206982 creator A5072670442 @default.
• W4379206982 creator A5081758013 @default.
• W4379206982 date "2023-06-03" @default.
• W4379206982 modified "2023-10-09" @default.
• W4379206982 title "Structural modification of resveratrol analogue exhibits anticancer activity against lung cancer stem cells via suppression of Akt signaling pathway" @default.
• W4379206982 cites W1968984443 @default.
• W4379206982 cites W1973152660 @default.
• W4379206982 cites W1987898553 @default.
• W4379206982 cites W1991557988 @default.
• W4379206982 cites W1994599132 @default.
• W4379206982 cites W2015244252 @default.
• W4379206982 cites W2020671379 @default.
• W4379206982 cites W2022388990 @default.
• W4379206982 cites W2030496908 @default.
• W4379206982 cites W2037535298 @default.
• W4379206982 cites W2058106363 @default.
• W4379206982 cites W2062069198 @default.
• W4379206982 cites W2063726085 @default.
• W4379206982 cites W2074020574 @default.
• W4379206982 cites W2087012714 @default.
• W4379206982 cites W2087479969 @default.
• W4379206982 cites W2087956154 @default.
• W4379206982 cites W2090898691 @default.
• W4379206982 cites W2095719702 @default.
• W4379206982 cites W2102085111 @default.
• W4379206982 cites W2117735955 @default.
• W4379206982 cites W2125649123 @default.
• W4379206982 cites W2132629607 @default.
• W4379206982 cites W2147993766 @default.
• W4379206982 cites W2168854899 @default.
• W4379206982 cites W2181371279 @default.
• W4379206982 cites W2216966119 @default.
• W4379206982 cites W2228249985 @default.
• W4379206982 cites W2318090527 @default.
• W4379206982 cites W2404280981 @default.
• W4379206982 cites W2419225477 @default.
• W4379206982 cites W2421665744 @default.
• W4379206982 cites W2465250101 @default.
• W4379206982 cites W2508173956 @default.
• W4379206982 cites W2565298700 @default.
• W4379206982 cites W2580622749 @default.
• W4379206982 cites W2584147907 @default.
• W4379206982 cites W2792495697 @default.
• W4379206982 cites W2794372787 @default.
• W4379206982 cites W2801437236 @default.
• W4379206982 cites W2911997094 @default.
• W4379206982 cites W2914628270 @default.
• W4379206982 cites W2924426209 @default.
• W4379206982 cites W2959290381 @default.
• W4379206982 cites W2973156882 @default.
• W4379206982 cites W2989313910 @default.
• W4379206982 cites W2999266339 @default.
• W4379206982 cites W3004733773 @default.
• W4379206982 cites W3005449057 @default.
• W4379206982 cites W3005689864 @default.
• W4379206982 cites W3045353567 @default.
• W4379206982 cites W3048565185 @default.
• W4379206982 cites W3083406432 @default.
• W4379206982 cites W3097145107 @default.
• W4379206982 cites W3108157233 @default.
• W4379206982 cites W3119005666 @default.
• W4379206982 cites W3148931375 @default.
• W4379206982 cites W3151260118 @default.
• W4379206982 cites W3164258172 @default.
• W4379206982 cites W3168436232 @default.
• W4379206982 cites W3177684048 @default.
• W4379206982 cites W4220675860 @default.
• W4379206982 cites W4224313580 @default.
• W4379206982 cites W4281871473 @default.
• W4379206982 cites W4315649460 @default.
• W4379206982 cites W4366135943 @default.
• W4379206982 cites W65155625 @default.
• W4379206982 doi "https://doi.org/10.1186/s12906-023-04016-6" @default.
• W4379206982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37270520" @default.
• W4379206982 hasPublicationYear "2023" @default.
• W4379206982 type Work @default.
• W4379206982 citedByCount "1" @default.
• W4379206982 countsByYear W43792069822023 @default.
• W4379206982 crossrefType "journal-article" @default.
• W4379206982 hasAuthorship W4379206982A5013984804 @default.
• W4379206982 hasAuthorship W4379206982A5019794851 @default.
• W4379206982 hasAuthorship W4379206982A5060090809 @default.
• W4379206982 hasAuthorship W4379206982A5061536229 @default.
• W4379206982 hasAuthorship W4379206982A5064398646 @default.
• W4379206982 hasAuthorship W4379206982A5065121008 @default.
• W4379206982 hasAuthorship W4379206982A5072670442 @default.
• W4379206982 hasAuthorship W4379206982A5081758013 @default.
• W4379206982 hasBestOaLocation W43792069821 @default.
• W4379206982 hasConcept C104317684 @default.
• W4379206982 hasConcept C121608353 @default.
• W4379206982 hasConcept C142724271 @default.
• W4379206982 hasConcept C153911025 @default.

• next